Mount Sinai Beth Israel Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2018
NCT03462927
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Department of Dermatology, Mount Sinai Beth Israel | Mount Sinai Beth Israel

Active Ingredients

Drugs in Phase 4 Trials (3)

amoxicillin (1 trial)

clarithromycin (biaxin) (1 trial)

omeprazole (prilosec) (1 trial)

Drugs in Phase 2 Trials (2)

betamethasone (celestone) (1 trial)

calcipotriene (dovonex) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 5